Zoetis’ second quarter saw revenue and adjusted earnings surpass Wall Street expectations, but the market responded ...

Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Animal health company Zoetis (NYSE:ZTS) reported in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company ...

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...

Zoetis Inc. closed 25.61% short of its 52-week high of $200.33, which the company reached on September 19th.

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.

Zoetis enjoys enviable financial flexibility, even as leverage ticked up in 2015 to finance the purchase of Pharmaq and Abbott's animal health business. With long-term debt at roughly $5.2 billion ...

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.